



Pfizer Europe MA EEIG

Boulevard de la Plaine 17,
1050 Brussels,
Belgium

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

05 December 2018

Dr Harald Enzmann
Chairman of the Committee for Medicinal Products for Human Use
European Medicines Agency
30 Churchill Place
Canary Wharf
London
E14 5EU
United Kingdom

Subject: Withdrawal of FYZOCLAD (adalimumab) Solution for Injection, EMEA/H/0005253

Dear Dr Harald Enzmann,

I would like to inform you that, at this point of time, Pfizer Europe MA EEIG has taken the decision to withdraw the application for Marketing Authorisation of FYZOCLAD (adalimumab), Solution for Injection, which was intended to be used for the following indications:

- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Axial spondyloarthritis
- Psoriatic arthritis
- Psoriasis and paediatric plaque psoriasis

PFIZER CONFIDENTIAL

Page 1


- Uveitis and paediatric uveitis

This withdrawal is based on the following reason: a change in Pfizer's strategy. This is unrelated to product quality or safety.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Sincerely,



Senior Manager, Regulatory Affairs
EU Regulatory Affairs – Biosimilars